Paysign, Inc. to Sponsor the 2024 Gene Therapy for Rare Disorders Conference March 26-29

Rhea-AI Summary

Paysign, Inc. (PAYS) announces their first-time sponsorship of the 7th Annual Gene Therapy for Rare Disorders conference. The conference aims to address challenges in gene therapy for rare disorders, with Paysign focusing on patient affordability solutions. Matthew Turner, President of Patient Affordability at Paysign, highlights the company's commitment to improving access to gene therapy.

BOSTON--(BUSINESS WIRE)-- Paysign, Inc. (NASDAQ: PAYS), a leading provider of prepaid card programs, comprehensive patient affordability offerings, digital banking services and integrated payment processing, today announced their first-time sponsorship of the 7^th Annual Gene Therapy for Rare Disorders conference to be held March 26-29, 2024, in Boston, Massachusetts.

In keeping with their commitment to patient affordability and access, Paysign is sponsoring the annual event as an Exhibition Partner. The conference is the gene therapy industry’s leading event where key figures, service providers, payers and regulators discuss insights to the crucial challenges that face these programs today.

"We are thrilled to add this event to our annual schedule of sponsorships and to provide much-needed representation for patient affordability solutions that tackle the biggest issues facing access to gene therapy for rare disorders,” said Matthew Turner, President, Patient Affordability at Paysign.

Stop by and see the Paysign team at their booth to network and gain fundamental insights on how to mitigate barriers to patient access. To learn more about Paysign’s patient affordability solutions, visit paysign.com/rx.

Visit the Gene Therapy for Rare Disorders conference website to learn more and register for the event.

About Paysign

Paysign, Inc. is a leading provider of prepaid card programs, comprehensive patient affordability offerings, digital banking services, and integrated payment processing designed for businesses, consumers and government institutions. Founded in 2001 and headquartered in southern Nevada, the company creates customized, innovative payment solutions for clients across all industries, including pharmaceutical, healthcare, hospitality, and retail. Built on the foundation of a reliable payments platform, Paysign’s end-to-end technologies securely enable digital payout solutions and facilitate the distribution of funds for donor compensation, copay assistance, customer incentives, employee rewards, travel expenses, per diem, reimbursements, rebates, gift cards and countless other exchanges of value. Paysign’s solutions lower costs, streamline operations and improve customer, employee and partner loyalty. To learn more, visit paysign.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240312706790/en/

Investor Relations

ir@paysign.com

888.522.4853

paysign.com/investors

Media Relations

Alicia Ches

702.749.7257

pr@paysign.com 

Source: Paysign, Inc.

FAQ

What event is Paysign sponsoring for the first time?

Paysign is sponsoring the 7th Annual Gene Therapy for Rare Disorders conference for the first time.

When and where will the conference take place?

The conference will be held in Boston, Massachusetts from March 26-29, 2024.

What is the focus of the conference?

The conference focuses on addressing challenges related to gene therapy for rare disorders.

Who is Matthew Turner and what is his role at Paysign?

Matthew Turner is the President of Patient Affordability at Paysign.

Why is Paysign sponsoring the conference?

Paysign is sponsoring the conference to provide representation for patient affordability solutions in gene therapy.